https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=212937
Erasca Announces Publication Of Promising Clinical Data Supporting The Therapeutic Potential Of Naporafenib In Combination With Trametinib In NRAS-Mutant Melanoma
Promising preliminary antitumor activity with the combination demonstrated in heavily pretreated patients
47% ORR, 5.5 months mPFS observed with preferred combination dose of naporafenib 200 mg BID plus
